Testing a new RAS inhibitor for advanced solid tumors
Part of Cancer clinical trials.
This trial is testing a new oral medication (AN9025) for people with advanced solid tumors that have a RAS mutation, such as pancreatic, colorectal, lung, or melanoma. It aims to see if the drug can shrink tumors or slow their growth when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- Your cancer must have a RAS mutation (KRAS, NRAS, or HRAS) confirmed by a lab test
- Your cancer has spread or is advanced, and standard treatments no longer work
- You are in generally good health (able to take care of yourself, with good kidney, liver, and heart function)
- You have not had a prior treatment that targets the same type of RAS pathway
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, AN4035, for people with advanced cancers that have a RAS mutation and high levels of a protein called CEACAM5. The drug may help shrink tumors or slow their growth.
This trial tests a new drug that targets cancers with a RAS mutation. It may help people whose cancer has grown after standard treatments.
This study tests a new drug (GFH276) combined with either cetuximab or chemotherapy for people with advanced solid tumors or pancreatic cancer that have a specific genetic change (RAS mutation). The goal is to see if this combination can shrink tumors or slow their growth.
This phase 1 trial tests an oral drug called PAS-004 for people with advanced solid tumors that have certain gene changes. It aims to find a safe dose and see if the drug can stop tumor growth.
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
This trial is testing an experimental drug for people whose cancer has spread and has a specific gene change called RAS. The study aims to see if the drug is safe and helps shrink tumors.
Hear when a new Solid Tumors (Phase 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.